Free Trial
→ Nvidia CEO Makes First Ever Tesla Announcement (From Brownstone Research) (Ad)tc pixel Free NAMSW Stock Alerts

NewAmsterdam Pharma (NAMSW) Financials

NewAmsterdam Pharma logo
$24.46 -2.23 (-8.34%)
As of 09:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for NewAmsterdam Pharma

Annual Income Statements for NewAmsterdam Pharma

This table shows NewAmsterdam Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -7.02 -32 -30 -177 -242
Consolidated Net Income / (Loss)		 -7.02 -32 -23 -177 -242
Net Income / (Loss) Continuing Operations		 -7.02 -32 -30 -177 -242
Total Pre-Tax Income 		-7.02 -32 -23 -177 -242
Total Operating Income		 -6.63 -34 -3.56 -183 -176
Total Gross Profit		 0.00 0.01 103 14 46
Total Revenue		 0.00 0.01 103 14 46
Operating Revenue		 0.00 0.01 103 14 46
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 6.63 34 106 197 222
Selling, General & Admin Expense		 1.69 5.44 20 38 70
Research & Development Expense		 4.94 28 87 159 151
Total Other Income / (Expense), net		 -0.42 1.39 -27 6.06 -65
Interest Expense		 0.42 0.24 0.29 0.00 0.00
Interest & Investment Income		 0.00 - 0.00 11 17
Other Income / (Expense), net		 - 1.63 -27 -5.23 -82
Income Tax Expense		 0.00 0.00 0.00 0.03 -0.00
Basic Earnings per Share		 ($0.76) - ($1.19) ($2.15) ($2.56)
Weighted Average Basic Shares Outstanding		 - - 81.56M 89.27M 109.82M
Diluted Earnings per Share		 ($0.76) ($1.37) ($1.19) ($2.15) ($2.56)
Weighted Average Diluted Shares Outstanding		 - - 81.56M 89.27M 109.82M
Weighted Average Basic & Diluted Shares Outstanding		 - - 81.56M 89.27M 109.82M

Quarterly Income Statements for NewAmsterdam Pharma

This table shows NewAmsterdam Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -42 -38 -47 -49 -94 -39 -17 -92 -40
Consolidated Net Income / (Loss)		 -42 -38 -47 -49 -94 -39 -17 -92 -40
Net Income / (Loss) Continuing Operations		 -42 -38 -47 -49 -94 -39 -17 -92 -40
Total Pre-Tax Income 		-42 -38 -47 -49 -94 -39 -17 -92 -40
Total Operating Income		 -40 -42 -50 -51 -55 -53 -25 -43 -69
Total Gross Profit		 8.63 1.72 2.94 0.80 1.40 2.28 29 13 2.98
Total Revenue		 8.63 1.72 2.94 0.80 1.40 2.28 29 13 2.98
Operating Revenue		 8.63 1.72 2.94 0.80 1.40 2.28 29 13 2.98
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 48 44 52 52 57 55 54 56 72
Selling, General & Admin Expense		 8.06 9.86 9.13 11 14 16 18 21 27
Research & Development Expense		 40 34 43 41 42 38 36 35 45
Total Other Income / (Expense), net		 -2.17 4.19 2.43 1.61 -38 14 8.36 -49 29
Interest & Investment Income		 0.94 4.61 3.06 2.67 3.08 4.87 4.44 4.49 7.35
Other Income / (Expense), net		 -3.11 -0.42 -0.63 -1.06 -41 8.70 3.91 -53 22
Income Tax Expense		 0.00 0.00 0.00 0.03 0.00 0.00 -0.00 - 0.00
Basic Earnings per Share		 ($0.51) ($0.47) ($0.57) ($0.60) ($1.06) ($0.41) ($0.18) ($0.91) ($0.34)
Weighted Average Basic Shares Outstanding		 - - - 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M
Diluted Earnings per Share		 ($0.51) ($0.47) ($0.57) ($0.60) ($1.06) ($0.41) ($0.18) ($0.91) ($0.34)
Weighted Average Diluted Shares Outstanding		 - - - 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M

Annual Cash Flow Statements for NewAmsterdam Pharma

This table details how cash moves in and out of NewAmsterdam Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 6.52 50 402 -132 438
Net Cash From Operating Activities		 -7.28 -28 11 -141 -159
Net Cash From Continuing Operating Activities		 -7.28 -28 11 -141 -159
Net Income / (Loss) Continuing Operations		 -7.02 -32 -23 -177 -242
Consolidated Net Income / (Loss)		 -7.02 -32 -23 -177 -242
Depreciation Expense		 0.00 0.02 0.01 0.05 0.11
Amortization Expense		 - - 0.00 0.00 -0.23
Non-Cash Adjustments To Reconcile Net Income		 0.39 -0.45 23 30 116
Changes in Operating Assets and Liabilities, net		 -0.65 4.32 10 5.87 -33
Net Cash From Investing Activities		 0.00 -0.02 -0.22 -0.02 -63
Net Cash From Continuing Investing Activities		 0.00 -0.02 -0.22 -0.02 -63
Purchase of Property, Plant & Equipment		 - -0.02 -0.22 -0.02 -0.67
Purchase of Investments		 - - 0.00 0.00 -62
Net Cash From Financing Activities		 14 78 392 8.91 660
Net Cash From Continuing Financing Activities		 14 78 392 8.91 660
Repurchase of Common Equity		 - 0.00 0.00 0.00 -0.54
Issuance of Common Equity		 - 78 397 0.00 0.00
Other Financing Activities, net		 - - -5.05 8.91 660
Cash Interest Paid		 - - 0.28 0.00 0.00
Cash Income Taxes Paid		 - - 0.00 0.03 0.00

Quarterly Cash Flow Statements for NewAmsterdam Pharma

This table details how cash moves in and out of NewAmsterdam Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -29 -23 -47 -33 143 -50 -13 357 -27
Net Cash From Operating Activities		 -32 -29 -47 -33 -55 -54 -13 -37 -36
Net Cash From Continuing Operating Activities		 -32 -29 -47 -33 -55 -54 -13 -37 -36
Net Income / (Loss) Continuing Operations		 -42 -38 -47 -49 -94 -39 -17 -92 -40
Consolidated Net Income / (Loss)		 -42 -38 -47 -49 -94 -39 -17 -92 -40
Depreciation Expense		 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.05 0.05
Amortization Expense		 - - - - - - - - -0.51
Non-Cash Adjustments To Reconcile Net Income		 9.31 11 2.98 6.08 50 -9.64 3.60 72 9.20
Changes in Operating Assets and Liabilities, net		 0.83 -2.46 -2.84 10 -11 -5.35 0.52 -17 -5.68
Net Cash From Investing Activities		 -0.01 -0.01 -0.01 -0.00 -0.39 -0.21 -0.08 -62 2.86
Net Cash From Continuing Investing Activities		 -0.01 -0.01 -0.01 -0.00 -0.39 -0.21 -0.08 -62 2.86
Purchase of Property, Plant & Equipment		 -0.01 -0.01 -0.01 -0.00 -0.39 -0.21 -0.08 -0.00 -0.02
Purchase of Investments		 - - - - - - - - -9.63
Sale and/or Maturity of Investments		 - - - - - - - - 13
Net Cash From Financing Activities		 2.39 6.33 0.19 - 198 4.66 0.06 457 6.52
Net Cash From Continuing Financing Activities		 2.39 6.33 0.19 - 198 4.66 0.06 457 6.52
Repurchase of Common Equity		 0.00 - - - -0.52 - - -0.03 -1.59
Other Financing Activities, net		 2.39 6.33 0.19 - 199 4.66 0.06 457 8.11

Annual Balance Sheets for NewAmsterdam Pharma

This table presents NewAmsterdam Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 68 569 347 865
Total Current Assets		 67 479 347 863
Cash & Equivalents		 60 469 340 772
Short-Term Investments		 - - 0.00 62
Prepaid Expenses		 0.00 0.16 6.34 24
Other Current Assets		 - - 0.00 4.95
Plant, Property, & Equipment, net		 0.22 0.15 0.05 0.24
Total Noncurrent Assets		 0.81 89 0.26 0.97
Goodwill		 - - 0.17 0.53
Other Noncurrent Operating Assets		 - - 0.09 0.43
Total Liabilities & Shareholders' Equity		 68 569 347 865
Total Liabilities		 11 50 59 107
Total Current Liabilities		 11 38 50 107
Accounts Payable		 11 20 28 18
Current Deferred Revenue		 0.00 14 8.94 6.01
Other Current Liabilities		 0.06 0.07 13 83
Total Noncurrent Liabilities		 0.13 12 8.81 0.20
Noncurrent Deferred Revenue		 0.00 4.81 1.02 0.00
Other Noncurrent Operating Liabilities		 0.00 12 7.79 0.20
Commitments & Contingencies		 - - 0.00 0.00
Total Equity & Noncontrolling Interests		 56 518 288 758
Total Preferred & Common Equity		 56 518 288 758
Total Common Equity		 56 518 288 758
Common Stock		 95 641 601 1,312
Retained Earnings		 - - -317 -559
Accumulated Other Comprehensive Income / (Loss)		 -39 -128 4.42 4.47

Quarterly Balance Sheets for NewAmsterdam Pharma

This table presents NewAmsterdam Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 488 447 439 818
Total Current Assets		 488 445 438 817
Cash & Equivalents		 481 431 423 748
Short-Term Investments		 - - - 60
Prepaid Expenses		 6.68 15 15 8.83
Other Current Assets		 - - - 0.00
Plant, Property, & Equipment, net		 0.10 0.23 0.23 0.24
Total Noncurrent Assets		 0.54 1.10 1.09 0.87
Goodwill		 0.49 0.54 0.59 0.50
Other Noncurrent Operating Assets		 0.05 0.56 0.49 0.37
Total Liabilities & Shareholders' Equity		 488 447 439 818
Total Liabilities		 77 59 60 41
Total Current Liabilities		 60 45 41 41
Accounts Payable		 19 15 18 14
Current Deferred Revenue		 8.12 6.06 4.50 3.03
Other Current Liabilities		 33 24 19 24
Total Noncurrent Liabilities		 17 14 19 0.14
Noncurrent Deferred Revenue		 0.44 0.22 0.00 0.00
Other Noncurrent Operating Liabilities		 16 14 19 0.14
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 412 387 379 777
Total Preferred & Common Equity		 412 387 379 777
Total Common Equity		 412 387 379 777
Common Stock		 818 833 841 1,371
Retained Earnings		 -411 -450 -466 -598
Accumulated Other Comprehensive Income / (Loss)		 4.42 4.42 4.42 4.43

Annual Metrics And Ratios for NewAmsterdam Pharma

This table displays calculated financial ratios and metrics derived from NewAmsterdam Pharma's official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 1,008,087.71% -86.28% 223.37%
EBITDA Growth		 0.00% -384.22% 6.34% -525.62% -37.44%
EBIT Growth		 0.00% -384.37% 6.36% -525.60% -37.35%
NOPAT Growth		 0.00% -409.00% 89.46% -5,043.86% 3.65%
Net Income Growth		 0.00% -360.89% 30.07% -681.73% -36.54%
EPS Growth		 0.00% -80.82% 13.11% -80.67% -19.07%
Operating Cash Flow Growth		 0.00% -291.24% 137.45% -1,424.13% -12.28%
Free Cash Flow Firm Growth		 0.00% 0.00% -176.58% 51.69% -269.23%
Invested Capital Growth		 0.00% 0.00% 1,464.64% -205.66% -47.32%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 35.63%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -20.91%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -20.81%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 4.26%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -21.46%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -13.78%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -2.86%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -74.82%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -315,217.31% -29.28% -1,335.30% -567.55%
Operating Margin		 0.00% -331,406.51% -3.46% -1,298.56% -386.91%
EBIT Margin		 0.00% -315,372.86% -29.29% -1,335.65% -567.30%
Profit (Net Income) Margin		 0.00% -317,772.91% -22.04% -1,255.76% -530.25%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.02% 100.00%
Interest Burden Percent		 105.89% 100.76% 75.24% 94.00% 93.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -10.91% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -3.29% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 3.03% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -57.44% -7.88% -43.87% -46.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -112.38% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -47.48% -9.45% -41.10% -42.66%
Return on Assets (ROA)		 0.00% -47.84% -7.11% -38.64% -39.88%
Return on Common Equity (ROCE)		 0.00% -57.44% -7.88% -43.87% -46.20%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -57.44% -4.37% -61.35% -31.89%
Net Operating Profit after Tax (NOPAT)		 -4.64 -24 -2.49 -128 -123
NOPAT Margin		 0.00% -231,984.56% -2.42% -908.99% -270.84%
Net Nonoperating Expense Percent (NNEP)		 0.00% -29.15% -7.62% -12.07% -20.12%
Return On Investment Capital (ROIC_SIMPLE)		 - - -0.48% -44.41% -16.29%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 53,367.71% 19.00% 267.09% 154.61%
R&D to Revenue		 0.00% 278,138.80% 84.47% 1,131.47% 332.30%
Operating Expenses to Revenue		 0.00% 331,506.51% 103.46% 1,398.56% 486.91%
Earnings before Interest and Taxes (EBIT)		 -6.63 -32 -30 -188 -258
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.63 -32 -30 -188 -259
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 3.16 3.13
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 3.16 3.14
Price to Revenue (P/Rev)		 0.00 0.00 0.00 64.66 52.11
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 40.49 33.80
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.06 -0.92 -1.00 -1.12
Leverage Ratio		 0.00 1.20 1.11 1.14 1.16
Compound Leverage Factor		 0.00 1.21 0.83 1.07 1.08
Debt to Total Capital		 0.00% 0.22% 0.01% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.22% 0.01% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 99.78% 99.99% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 1.87 15.60 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.01 -0.02 0.00 0.00
Net Debt to NOPAT		 0.00 2.54 188.39 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.01 -0.02 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 7.31 12.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 0.00 5.96 12.64 6.95 8.08
Quick Ratio		 0.00 5.96 12.64 6.82 7.80
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -20 -55 -27 -99
Operating Cash Flow to CapEx		 0.00% -125,820.00% 4,825.79% -588,408.33% -23,595.83%
Free Cash Flow to Firm to Interest Expense		 0.00 -81.89 -192.93 0.00 0.00
Operating Cash Flow to Interest Expense		 -17.32 -116.50 37.16 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -17.32 -116.59 36.39 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.32 0.03 0.08
Accounts Receivable Turnover		 0.00 0.00 12.21 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.05 556.47 140.86 316.41
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 234,496.84 29.90 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 234,496.84 29.90 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 0.00 -3.61 49 -52 -77
Invested Capital Turnover		 0.00 -0.01 4.50 -10.11 -0.71
Increase / (Decrease) in Invested Capital		 0.00 -3.61 53 -101 -25
Enterprise Value (EV)		 0.00 0.00 0.00 571 1,540
Market Capitalization		 0.00 0.00 0.00 911 2,374
Book Value per Share		 $0.00 $0.00 $6.36 $3.54 $8.20
Tangible Book Value per Share		 $0.00 $0.00 $5.26 $3.53 $8.19
Total Capital		 0.00 56 518 288 758
Total Debt		 0.00 0.13 0.06 0.00 0.00
Total Long-Term Debt		 0.00 0.13 0.06 0.00 0.00
Net Debt		 0.00 -60 -469 -340 -834
Capital Expenditures (CapEx)		 0.00 0.02 0.22 0.02 0.67
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.64 -28 -44 -78
Debt-free Net Working Capital (DFNWC)		 0.00 55 441 297 756
Net Working Capital (NWC)		 0.00 55 441 297 756
Net Nonoperating Expense (NNE)		 2.38 8.74 20 49 118
Net Nonoperating Obligations (NNO)		 0.00 -60 -469 -340 -834
Total Depreciation and Amortization (D&A)		 0.00 0.02 0.01 0.05 -0.11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -45,534.23% -26.93% -309.13% -170.52%
Debt-free Net Working Capital to Revenue		 0.00% 544,388.46% 429.90% 2,107.13% 1,660.33%
Net Working Capital to Revenue		 0.00% 544,388.46% 429.90% 2,107.13% 1,660.33%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($2.15) ($2.56)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 89.27M 109.82M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.15) ($2.56)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 89.27M 109.82M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 89.27M 109.82M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.64 -24 -2.49 -128 -123
Normalized NOPAT Margin		 0.00% -231,984.56% -2.42% -908.99% -270.84%
Pre Tax Income Margin		 0.00% -317,772.91% -22.04% -1,255.57% -530.25%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -15.78 -131.40 -104.82 0.00 0.00
NOPAT to Interest Expense		 -11.05 -96.66 -8.68 0.00 0.00
EBIT Less CapEx to Interest Expense		 -15.78 -131.50 -105.59 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -11.05 -96.75 -9.45 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -0.22%

Quarterly Metrics And Ratios for NewAmsterdam Pharma

This table displays calculated financial ratios and metrics derived from NewAmsterdam Pharma's official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -83.76% 32.73% 889.83% 1,490.54% 112.56%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% -125.45% -2.25% 58.02% -85.35% 51.11%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% -125.44% -2.27% 57.98% -85.40% 51.60%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -39.22% -23.76% 49.55% 15.36% -24.23%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -123.16% -1.87% 64.68% -86.24% 57.85%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -107.84% 12.77% 68.42% -51.67% 67.92%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -71.36% -84.20% 73.39% -13.32% 33.21%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -383.47%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -47.32% 55.13%
Revenue Q/Q Growth		 0.00% -80.10% 71.29% -72.70% 0.00% 62.67% 1,177.36% -56.13% -76.68%
EBITDA Q/Q Growth		 0.00% 0.14% -16.99% -3.88% 0.00% 54.71% 51.97% -358.68% 51.00%
EBIT Q/Q Growth		 0.00% 0.13% -16.99% -3.87% 0.00% 54.70% 51.93% -358.31% 51.50%
NOPAT Q/Q Growth		 0.00% -6.60% -16.66% -3.06% 0.00% 5.24% 52.44% -72.90% -59.44%
Net Income Q/Q Growth		 0.00% 8.87% -23.09% -5.01% 0.00% 58.40% 57.32% -453.72% 57.12%
EPS Q/Q Growth		 0.00% 7.84% -21.28% -5.26% 0.00% 61.32% 56.10% -405.56% 62.64%
Operating Cash Flow Q/Q Growth		 0.00% 8.03% -60.30% 29.59% 0.00% 1.14% 76.84% -199.80% 2.70%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -78.80% 307.72% -121.34% -1,436.75%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 37.60% -1.38% -74.82% 59.43%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -497.76% -2,498.02% -1,706.15% -6,491.03% -6,911.85% -1,924.44% -72.35% -756.43% -1,589.62%
Operating Margin		 -461.85% -2,474.20% -1,685.07% -6,360.40% -3,960.17% -2,306.93% -85.89% -338.47% -2,314.47%
EBIT Margin		 -497.87% -2,498.78% -1,706.63% -6,492.65% -6,912.92% -1,925.27% -72.45% -756.83% -1,574.14%
Profit (Net Income) Margin		 -486.94% -2,230.11% -1,602.62% -6,163.76% -6,692.86% -1,711.58% -57.18% -721.71% -1,327.30%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.05% 100.00% 100.00% 99.99% 100.00% 100.00%
Interest Burden Percent		 97.81% 89.25% 93.91% 94.88% 96.82% 88.90% 78.93% 95.36% 84.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -43.87% -55.53% -59.21% -52.50% -46.20% -31.51%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -199.79% -97.11% -32.00% -5.54% -56.92% -113.56%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -189.67% -94.02% -28.45% -4.37% -54.28% -95.75%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -43.87% -55.53% -59.21% -52.50% -46.20% -31.51%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% -55.53% -59.21% -52.50% 0.00% -24.10%
Net Operating Profit after Tax (NOPAT)		 -28 -30 -35 -36 -39 -37 -18 -30 -48
NOPAT Margin		 -323.29% -1,731.94% -1,179.55% -4,452.28% -2,772.12% -1,614.85% -60.12% -236.93% -1,620.13%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -4.04% -22.83% -1.02% 0.40% -10.54% 1.35%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -12.40% - - - -3.99% -6.21%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 93.43% 574.14% 310.37% 1,318.18% 1,031.62% 722.90% 63.25% 165.25% 911.75%
R&D to Revenue		 468.42% 2,000.06% 1,474.70% 5,142.22% 3,028.55% 1,684.03% 122.64% 273.21% 1,502.72%
Operating Expenses to Revenue		 561.85% 2,574.20% 1,785.07% 6,460.40% 4,060.17% 2,406.93% 185.89% 438.47% 2,414.47%
Earnings before Interest and Taxes (EBIT)		 -43 -43 -50 -52 -97 -44 -21 -97 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -43 -43 -50 -52 -97 -44 -21 -97 -47
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 3.16 4.68 4.46 3.94 3.13 2.89
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 3.16 4.69 4.47 3.95 3.14 2.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 64.66 281.10 232.82 44.48 52.11 47.69
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 40.49 210.98 174.80 31.90 33.80 30.54
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -1.18 -1.17 -1.11 -1.12 -1.12 -1.08
Leverage Ratio		 0.00 0.00 0.00 1.14 1.19 1.15 1.16 1.16 1.10
Compound Leverage Factor		 0.00 0.00 0.00 1.08 1.15 1.03 0.92 1.10 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 8.60 14.33 16.86 14.38 13.13 32.84
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 6.95 8.17 9.83 10.61 8.08 19.98
Quick Ratio		 0.00 0.00 0.00 6.82 8.06 9.51 10.25 7.80 19.76
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 31 6.47 26 -5.63 -86
Operating Cash Flow to CapEx		 -455,185.71% -586,100.00% -521,955.56% -1,102,466.67% -14,182.34% -25,827.27% -16,669.33% -1,249,366.67% -227,925.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.03 0.01 0.02 0.08 0.08 0.07
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 140.86 67.94 31.73 145.43 316.41 278.11
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -52 -69 -43 -44 -77 -31
Invested Capital Turnover		 0.00 0.00 0.00 -0.27 -0.20 -0.34 -1.53 -0.71 -0.94
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 -69 -43 -44 -25 38
Enterprise Value (EV)		 0.00 0.00 0.00 571 1,448 1,298 1,072 1,540 1,439
Market Capitalization		 1,081 970 754 911 1,929 1,728 1,494 2,374 2,248
Book Value per Share		 $0.00 $0.00 $0.00 $3.54 $4.58 $4.31 $4.21 $8.20 $7.08
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $3.53 $4.57 $4.30 $4.20 $8.19 $7.07
Total Capital		 0.00 0.00 0.00 288 412 387 379 758 777
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -340 -481 -431 -423 -834 -808
Capital Expenditures (CapEx)		 0.01 0.01 0.01 0.00 0.39 0.21 0.08 0.00 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -44 -53 -31 -26 -78 -32
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 297 428 400 397 756 776
Net Working Capital (NWC)		 0.00 0.00 0.00 297 428 400 397 756 776
Net Nonoperating Expense (NNE)		 14 8.55 12 14 55 2.20 -0.86 62 -8.72
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -340 -481 -431 -423 -834 -808
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.05 -0.46
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -309.13% -773.11% -413.03% -77.72% -170.52% -68.07%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 2,107.13% 6,238.65% 5,388.54% 1,180.62% 1,660.33% 1,646.99%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 2,107.13% 6,238.65% 5,388.54% 1,180.62% 1,660.33% 1,646.99%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.60) ($1.06) ($0.41) ($0.18) ($0.91) ($0.34)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.60) ($1.06) ($0.41) ($0.18) ($0.91) ($0.34)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 89.27M 89.98M 90.02M 92.39M 109.82M 112.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -30 -35 -36 -39 -37 -18 -30 -48
Normalized NOPAT Margin		 -323.29% -1,731.94% -1,179.55% -4,452.28% -2,772.12% -1,614.85% -60.12% -236.93% -1,620.13%
Pre Tax Income Margin		 -486.94% -2,230.11% -1,602.62% -6,160.40% -6,692.86% -1,711.58% -57.19% -721.71% -1,327.30%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.22% -0.86%

Financials Breakdown Chart

Key Financial Trends

NewAmsterdam Pharma (NAMS) Financial Overview:

NewAmsterdam Pharma's recent quarterly results show a company still operating at a significant net loss, although there are some noteworthy changes and trends across the last several quarters.

  • Operating Revenues increased substantially in Q4 2024 ($12.8M) and Q3 2024 ($29.1M), compared to $803K in Q4 2023 and under $3M in earlier quarters of 2023, indicating improving top-line growth.
  • Cash and Equivalents at the end of Q1 2025 stood very strong at $748.4M, more than doubling from $422.7M at the end of Q3 2024 and up from ~$388M at the end of 2023, supporting liquidity and operational needs.
  • Other Income/ (Expense), net improved significantly to $22M in Q1 2025 from negative figures in prior quarters, adding a $29.4M boost to pre-tax income for Q1 2025.
  • Interest and Investment Income showed considerable growth, reaching $7.35M in Q1 2025 versus about $4.4-$4.8M in the prior quarters, suggesting better returns on cash or investments.
  • Total operating expenses rose sharply to $71.9M in Q1 2025 compared to $54.8M in Q4 2024 and around $44-54M range in 2023 quarters, mainly driven by higher R&D ($44.8M) and S,G&A expenses ($27.2M), indicating increased investment in product development and operations.
  • Net cash from continuing operating activities remains negative, with -$36.5M in Q1 2025, similar to Q4 2024 (-$37.5M), indicating continued cash burn from operations.
  • Long-term liabilities remain low ($137K as of Q1 2025), indicating minimal long-term debt obligations.
  • Net loss attributable to common shareholders remains large, at -$39.5M in Q1 2025 with EPS at -$0.34, showing continuing lack of profitability despite revenue growth.
  • Total operating income is deeply negative at -$68.9M in Q1 2025, reflecting high expenses relative to revenues.
  • Net change in cash and equivalents was negative $27.1M in Q1 2025, showing cash used during the quarter despite strong liquidity overall.

Summary: Over the past year, NewAmsterdam Pharma has demonstrated meaningful revenue growth and a strengthened cash position, supported by increased interest and investment income. However, the company continues to report large operating losses and negative net income, driven by substantial operating expenses, especially research and development. Cash flow from operations remains negative, consistent with an investing phase typical for biopharmaceutical companies. Investors should watch for progress in revenue growth and expense management to narrow losses, as well as the path to profitability.

10/24/25 10:52 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About NewAmsterdam Pharma's Financials

When does NewAmsterdam Pharma's financial year end?

According to the most recent income statement we have on file, NewAmsterdam Pharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has NewAmsterdam Pharma's net income changed over the last 4 years?

NewAmsterdam Pharma's net income appears to be on an upward trend, with a most recent value of -$241.60 million in 2024, rising from -$7.02 million in 2020. The previous period was -$176.94 million in 2023.

What is NewAmsterdam Pharma's operating income?
NewAmsterdam Pharma's total operating income in 2024 was -$176.29 million, based on the following breakdown:
  • Total Gross Profit: $45.56 million
  • Total Operating Expenses: $221.85 million
How has NewAmsterdam Pharma's revenue changed over the last 4 years?

Over the last 4 years, NewAmsterdam Pharma's total revenue changed from $0.00 in 2020 to $45.56 million in 2024, a change of 4,556,300,000.0%.

How much debt does NewAmsterdam Pharma have?

NewAmsterdam Pharma's total liabilities were at $107.12 million at the end of 2024, a 82.5% increase from 2023, and a 847.3% increase since 2021.

How much cash does NewAmsterdam Pharma have?

In the past 3 years, NewAmsterdam Pharma's cash and equivalents has ranged from $60.09 million in 2021 to $771.74 million in 2024, and is currently $771.74 million as of their latest financial filing in 2024.

How has NewAmsterdam Pharma's book value per share changed over the last 4 years?

Over the last 4 years, NewAmsterdam Pharma's book value per share changed from 0.00 in 2020 to 8.20 in 2024, a change of 819.9%.


Related Companies

This page (NASDAQ:NAMSW) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners
NEW LAW: Congress Approves Setup For Digital Dollar?
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...
Goldco Precious Metals | Sponsoredtc pixel
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsoredtc pixel
Apple's secret partner
The Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...
The Oxford Club | Sponsoredtc pixel
Trump cannot stop this train
Gallup reports that two-thirds of Americans now view socialism favorably — a shocking shift that one analyst s...
Porter & Company | Sponsoredtc pixel
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...
Angel Publishing | Sponsoredtc pixel
Gold surges past $4,200 … but this has beat gold by 1,000x
Gold has surged past $4,200 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...
Weiss Ratings | Sponsoredtc pixel
Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...
Brownstone Research | Sponsoredtc pixel
Next opportunity for crypto millions
The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...
Crypto 101 Media | Sponsoredtc pixel